GBIO - Generation Bio Co.
IEX Last Trade
1.07
-1.530 -142.991%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:18:54 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$2.60
-1.53
-58.85%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-10.08%
1 Month
-23.57%
3 Months
-57.87%
6 Months
-62.19%
1 Year
-43.98%
2 Year
-74.58%
Key data
Stock price
$1.07
DAY RANGE
$1.06 - $2.60
52 WEEK RANGE
$1.10 - $4.65
52 WEEK CHANGE
-$41.53
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Cameron G. McDonough
Region: US
Website: generationbio.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: generationbio.com
Employees: 150
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Generation Bio Co. develops therapies for the treatment of rare and prevalent diseases. The company was formerly known as Torus Therapeutics, Inc. It focuses on the diseases of skeletal muscle, central nervous system, and oncology.
Recent news